secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001819790-22-000039
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Q3 net loss $22.5M; NDA accepted for TP-03 with PDUFA Aug 2023
---------------------------------------------------------------------

- Net loss of $22.5M in Q3 2022 vs $15.7M in Q3 2021; R&D expense $10.9M, G&A $12.0M.
- Cash and marketable securities $226.6M at Sep 30, 2022; runway into at least 2026.
- FDA accepted TP-03 NDA for Demodex blepharitis; PDUFA target action date Aug 25, 2023.
- Board changes: Scott Morrison appointed Audit Chair; Chairman Ackermann to depart; CEO Azamian expected to become Chairman.
- Expected $30M milestones from LianBio out-license: $10M Dec 2022, $5M Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979022000039/0001819790-22-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979022000039/tars-20221109.htm
  HTML page:      https://secwatch.observer/filing/0001819790-22-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer